This site is intended for healthcare professionals
3d rendered medically accurate illustration of a womans large intestine
Ulcerative Colitis Learning Zone
Declaration of sponsorship Bristol Myers Squibb

Expert opinion on ulcerative colitis

Declaration of sponsorship Bristol Myers Squibb
Read time: 30 mins
Last updated:1st May 2024
Published:21st Sep 2023

Challenges and treatment options in UC

Meet Dr Tim Raine

Chapter 1: Meet Dr Tim Raine. Chapter 2: Key challenges in UC management and their impact. Chapter 3: Treatment goals and targets for UC management. Chapter 4: Benefits and limitations of corticosteroids in UC. Chapter 5: Current treatment options for UC. Chapter 6: Targeted small molecules and biologics in UC. Chapter 7: Clinical trials in UC: Design and key endpoints. Chapter 8: Considerations for appropriate treatment selection.

Gastroenterologist Dr Tim Raine (Cambridge University Hospitals, UK) takes a closer look at the treatment options available to people with ulcerative colitis (UC) and reviews the treatment goals that have the most impact on the daily lives of people with UC. Dr Raine also highlights the role of biologics and targeted small molecule treatments in UC management, and the importance of patient preference.

Unmet needs, clinical trials and treatment approvals in UC

Meet Professor Stephen B. Hanauer

Chapter 1: Meet Professor Stephen B. Hanauer. Chapter 2: Key unmet needs in ulcerative colitis. Chapter 3: Clinical trials for targeted small molecules in UC. Chapter 4: Clinical trials for biologics in UC. Chapter 5: Approvals for targeted small molecules in UC. Chapter 6: Individualised treatment selection in UC. Chapter 7: The importance of timely treatment progression.

What is the impact of unmet needs on the management of moderate-to-severe ulcerative colitis (UC), and why is timely treatment progression important? Gastroenterologist Professor Stephen Hanauer (Northwestern University, USA), focuses on the impacts of delayed access to biologics and targeted small molecules in the USA, as well as clinical trial evidence for UC treatments and individualised treatment selection in UC.

More about unmet needs in UC management

The role of biologics and targeted small molecules in UC

More about Dr Raine and Professor Hanauer

Welcome: